Literature DB >> 24142568

Massive breast necrosis after extravasation of a full anthracycline cycle.

Ines Vasconcelos1, Winfried Schoenegg.   

Abstract

A 57-year-old woman with invasive breast cancer was referred for adjuvant chemotherapy after undergoing breast conservative therapy and axillary dissection. A port was inserted in the contralateral subclavian vein and epirubicin, cyclophosphamide and 5-fluorouracil was the treatment of choice. After the first cycle, the patient was sent home. The following day, she reported rapidly developing redness and pain in the right breast and diagnosis of epirubicin extravasation was made. She was hospitalised, the port was surgically removed and approximately two-thirds of the breast underwent tissue necrosis. The necrotic tissue was resected and a skin graft was harvested from the thigh. She was offered DIEP-flap reconstruction 8 months later. There were no complications, except for marginal necrosis of the flap. Necrosectomy was performed and resolved through an advancement flap.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24142568      PMCID: PMC3822217          DOI: 10.1136/bcr-2013-201179

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  Extravasation: a dreaded complication of chemotherapy.

Authors:  D L Schrijvers
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

2.  Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing.

Authors:  Nagi El-Saghir; Zaher Otrock; Afif Mufarrij; Yasser Abou-Mourad; Ziad Salem; Ali Shamseddine; Jaber Abbas
Journal:  Lancet Oncol       Date:  2004-05       Impact factor: 41.316

3.  Treatment of anthracycline extravasation with dexrazoxane.

Authors:  S W Langer; M Sehested; P B Jensen
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

4.  Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.

Authors:  H T Mouridsen; S W Langer; J Buter; H Eidtmann; G Rosti; M de Wit; P Knoblauch; A Rasmussen; K Dahlstrøm; P B Jensen; G Giaccone
Journal:  Ann Oncol       Date:  2006-12-21       Impact factor: 32.976

5.  Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study.

Authors:  G Bertelli; A Gozza; G B Forno; M G Vidili; S Silvestro; M Venturini; L Del Mastro; O Garrone; R Rosso; D Dini
Journal:  J Clin Oncol       Date:  1995-11       Impact factor: 44.544

6.  Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse.

Authors:  R T Dorr; D S Alberts
Journal:  Cancer Treat Rep       Date:  1983-05

7.  The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse.

Authors:  R T Dorr; D S Alberts; H S Chen
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.